Wakamoto Pharmaceutical Co., Ltd. Statistics
Want to see JP:4512 full AI Analyst Report?
Wakamoto Pharmaceutical Co., Ltd. (4512) Stock Statistics & Valuation Metrics
Total Valuation
Wakamoto Pharmaceutical Co., Ltd. has a market cap or net worth of JPY 9.72B. The enterprise value is JPY 9.70B.
- Market Cap
- JPY 9.72B
- Enterprise Value
- JPY 9.70B
Share Statistics
Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 34,838,326
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Wakamoto Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.63%.
- Return on Equity (ROE)
- 0.02
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 1.63%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 32.70M
- Profits Per Employee
- 749.88K
- Employee Count
- 303
- Asset Turnover
- 0.60
- Inventory Turnover
- 1.32
Valuation Ratios
The current PE Ratio of Wakamoto Pharmaceutical Co., Ltd. is 28.70. Wakamoto Pharmaceutical Co., Ltd.’s PEG ratio is 0.02.
- PE Ratio
- 28.70
- PS Ratio
- 0.97
- PB Ratio
- 0.84
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Wakamoto Pharmaceutical Co., Ltd. had revenue of 9.91B and earned 227.22M in profits. Earnings per share was 6.55.
- Revenue
- 9.91B
- Gross Profit
- 4.73B
- Operating Income
- 255.54M
- Pretax Income
- 256.40M
- Net Income
- 227.22M
- EBITDA
- 701.22M
- Earnings Per Share (EPS)
- 6.55
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Wakamoto Pharmaceutical Co., Ltd. pays an annual dividend of JPY 3.00, resulting in a dividend yield of 1.25%
- Dividend Per Share
- JPY 3.00
- Dividend Yield
- 1.25%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- 3.56%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- -3.11%
- 50-Day Moving Average
- 299.36
- 200-Day Moving Average
- 303.94
- Relative Strength Index (RSI)
- 31.17
- Average Volume (3m)
- 39.88K
Important Dates
Wakamoto Pharmaceutical Co., Ltd. upcoming earnings date is Feb 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- Mar 30, 2026
Financial Position
Wakamoto Pharmaceutical Co., Ltd. as a current ratio of 3.48, with Debt / Equity ratio of 3.33%
- Current Ratio
- 3.48
- Quick Ratio
- 2.07
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -2.29
- Interest Coverage Ratio
- 134.85
Taxes
In the past 12 months, Wakamoto Pharmaceutical Co., Ltd. has paid 29.18M in taxes.
- Income Tax
- 29.18M
- Effective Tax Rate
- 0.11
Enterprise Valuation
Wakamoto Pharmaceutical Co., Ltd. EV to EBITDA ratio is 11.52, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.80
- EV to EBITDA
- 11.52
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Wakamoto Pharmaceutical Co., Ltd. has JPY 3.56B in cash and marketable securities with JPY 100.00M in debt, giving a net cash position of JPY 3.46B billion.
- Cash & Marketable Securities
- JPY 3.56B
- Total Debt
- JPY 100.00M
- Net Cash
- JPY 3.46B
- Net Cash Per Share
- JPY 99.33
- Tangible Book Value Per Share
- JPY 327.78
Margins
Gross margin is 45.87%, with operating margin of 2.58%, and net profit margin of 3.37%.
- Gross Margin
- 45.87%
- Operating Margin
- 2.58%
- Pretax Margin
- 4.12%
- Net Profit Margin
- 3.37%
- EBITDA Margin
- 6.91%
- EBIT Margin
- 2.35%
Analyst Forecast
The average price target for Wakamoto Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 23.41%
- EPS Growth Forecast
- 149.71%
Scores
- Smart Score
- ―
- AI Score
- 59.25
